Last reviewed · How we verify

Ceredist — Competitive Intelligence Brief

Ceredist (TALTIRELIN) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: taltirelin. Area: Other.

phase 2 taltirelin Thyrotropin-releasing hormone receptor Other Recombinant protein Live · refreshed every 30 min

Target snapshot

Ceredist (TALTIRELIN). Ceredist works by binding to the thyrotropin-releasing hormone receptor, which helps to regulate certain bodily functions.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ceredist TARGET TALTIRELIN phase 2 taltirelin Thyrotropin-releasing hormone receptor
Lopremone PROTIRELIN marketed protirelin Thyrotropin-releasing hormone receptor 1976-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (taltirelin class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ceredist — Competitive Intelligence Brief. https://druglandscape.com/ci/taltirelin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing